vs
Side-by-side financial comparison of Ellington Financial Inc. (EFC) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
Ellington Financial Inc. is the larger business by last-quarter revenue ($78.2M vs $75.5M, roughly 1.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 8.7%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 1.8%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
EFC vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $75.5M |
| Net Profit | $22.6M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 7.4% | 22.7% |
| Net Margin | 28.9% | — |
| Revenue YoY | 8.7% | 27.7% |
| Net Profit YoY | -26.2% | — |
| EPS (diluted) | $0.10 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $78.2M | $75.5M | ||
| Q3 25 | $82.8M | $54.5M | ||
| Q2 25 | $92.5M | $52.4M | ||
| Q1 25 | $82.9M | $46.0M | ||
| Q4 24 | $72.0M | $59.1M | ||
| Q3 24 | $67.0M | $80.5M | ||
| Q2 24 | $91.2M | $47.1M | ||
| Q1 24 | $75.5M | $43.8M |
| Q4 25 | $22.6M | — | ||
| Q3 25 | $29.5M | $8.8M | ||
| Q2 25 | $42.9M | $5.9M | ||
| Q1 25 | $31.6M | $3.0M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $16.2M | $20.3M | ||
| Q2 24 | $52.3M | $-4.5M | ||
| Q1 24 | $26.9M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 7.4% | 22.7% | ||
| Q3 25 | 31.1% | 17.6% | ||
| Q2 25 | 38.3% | 12.7% | ||
| Q1 25 | 37.3% | 8.7% | ||
| Q4 24 | 28.0% | 22.6% | ||
| Q3 24 | 24.0% | 27.4% | ||
| Q2 24 | 52.8% | -4.6% | ||
| Q1 24 | 42.2% | -5.3% |
| Q4 25 | 28.9% | — | ||
| Q3 25 | 35.7% | 16.2% | ||
| Q2 25 | 46.4% | 11.2% | ||
| Q1 25 | 38.2% | 6.5% | ||
| Q4 24 | 42.6% | — | ||
| Q3 24 | 24.1% | 25.2% | ||
| Q2 24 | 57.4% | -9.6% | ||
| Q1 24 | 35.6% | -11.0% |
| Q4 25 | $0.10 | $0.26 | ||
| Q3 25 | $0.29 | $0.17 | ||
| Q2 25 | $0.45 | $0.12 | ||
| Q1 25 | $0.35 | $0.06 | ||
| Q4 24 | $0.23 | $0.40 | ||
| Q3 24 | $0.19 | $0.41 | ||
| Q2 24 | $0.62 | $-0.09 | ||
| Q1 24 | $0.32 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.8B | $130.3M |
| Total Assets | $19.4B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $201.9M | $97.5M | ||
| Q3 25 | $184.8M | $94.4M | ||
| Q2 25 | $211.0M | $96.0M | ||
| Q1 25 | $203.3M | $93.2M | ||
| Q4 24 | $192.4M | $101.0M | ||
| Q3 24 | $217.7M | $96.7M | ||
| Q2 24 | $198.5M | $96.8M | ||
| Q1 24 | $187.5M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.8B | $130.3M | ||
| Q3 25 | $1.8B | $115.3M | ||
| Q2 25 | $1.7B | $104.7M | ||
| Q1 25 | $1.6B | $97.1M | ||
| Q4 24 | $1.6B | $92.1M | ||
| Q3 24 | $1.6B | $71.1M | ||
| Q2 24 | $1.6B | $48.5M | ||
| Q1 24 | $1.5B | $51.0M |
| Q4 25 | $19.4B | $216.3M | ||
| Q3 25 | $17.8B | $202.9M | ||
| Q2 25 | $17.1B | $194.9M | ||
| Q1 25 | $16.6B | $196.2M | ||
| Q4 24 | $16.3B | $213.3M | ||
| Q3 24 | $16.0B | $220.7M | ||
| Q2 24 | $15.1B | $205.0M | ||
| Q1 24 | $15.1B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-925.5M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -40.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-925.5M | $14.4M | ||
| Q3 25 | $-290.4M | $9.7M | ||
| Q2 25 | $-210.5M | $14.1M | ||
| Q1 25 | $-126.4M | $3.6M | ||
| Q4 24 | $-430.5M | $15.6M | ||
| Q3 24 | $-141.7M | $11.0M | ||
| Q2 24 | $-88.6M | $1.0M | ||
| Q1 24 | $-59.5M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 0.0% |
| Q4 25 | -40.92× | — | ||
| Q3 25 | -9.84× | 1.10× | ||
| Q2 25 | -4.90× | 2.41× | ||
| Q1 25 | -3.99× | 1.21× | ||
| Q4 24 | -14.04× | — | ||
| Q3 24 | -8.76× | 0.54× | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
